| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0002 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0005 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.1 | 0.0006 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0006 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | -0.098 | 0.003 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.095 | 0.003 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.003 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.09 | 0.004 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.31 | 0.004 |